Reuters India |
 Merck to stop development of hepatitis C treatments
Reuters (Reuters) - U.S. drugmaker Merck & Co said on Friday it would discontinue developing an experimental drug combination for chronic hepatitis C, as competition rises and patient population shrinks. The decision was made after reviewing mid-stage trial ... Merck Discontinues MK-3682B, MK-3682C Development Programs For HCV Infection |
from Health - Google News http://ift.tt/2xKGQWU
EmoticonEmoticon